[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595953":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":52,"collaborators":10,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Jordan Collaborating Cardiology Group","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adult patients admitted for acute coronary syndrome via the ED",null,"Patients with ACS presenting to the ED with a planned coronary angiography for possible coronary revascularization who get aspirin in the ED will be evaluated for bleeding and major cardiovascular events when they receive a second antiplatelet agent in the ED compared with in the cath lab.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Ayman Hammoudeh, MD, FACC","CONTACT","+96265001000","hammoudeh_ayman@yahoo.com",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Laith Habahbeh, MD","065001000","researchcultire2020@gmail.com",[23,38],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Jordan University Hospital","RECRUITING","Amman","11180","Jordan","JO",{"type":31,"coordinates":32},"Point",[33,34],35.94503,31.95522,{"lat":34,"lon":33},[37],{"name":14,"role":15,"phone":20,"phoneExt":10,"email":17},{"facility":39,"status":40,"city":26,"state":10,"zip":41,"country":28,"countryCode":29,"cosmosGeoPoint":42,"geoPoint":44,"contacts":45},"Istishari Hospital","NOT_YET_RECRUITING","11184",{"type":31,"coordinates":43},[33,34],{"lat":34,"lon":33},[46,47,49],{"name":14,"role":15,"phone":20,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":10,"email":48},"researchculture2020@gmail.com",{"name":50,"role":51,"phone":10,"phoneExt":10,"email":10},"Rashid Hnaiti, MD","SUB_INVESTIGATOR",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ayman J Hammoudeh, MD, FACC","Director, Department of Clinical Research; Director, Department of Internal Medicine","100595953",false,"NCT07039149","Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents","Dual Antiplatelet Agents Therapy in the Emergency Department for Acute Coronary Syndrome (The DATES Study).","DATES","Inclusion Criteria:\n\n* Adult patients\n* Presenting with acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, and unstable angina).\n* Antiplatelet medication (s) prescribed during index admission to hospital.\n* Willingness of the patient to be called for follow up up to 1 year after index hospitalization.\n\nExclusion Criteria:\n\n* Non cardiac chest pain.\n* No administration of antiplatelet agents during hospitalization.\n* Refusal of contact for follow up.","ALL","18 Years",{"count":66,"type":67},200,"ESTIMATED","1 Year","OBSERVATIONAL","This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab. What is the outcome when the 2 agents are given n the ER?",[72,73],"Major Bleeding","Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)",[75,76,77],"Dual antiplatelet therapy","Pretreatment with DAPT","Acute coronary syndrome","2025-11-26",{"date":80,"type":81},"2025-11-28","ACTUAL",{"date":83,"type":81},"2025-08-01",{"date":85,"type":67},"2026-11-01",{"name":5,"class":6},2]